Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2009
03/19/2009WO2009033722A2 Use of a octreotide as a therapeutic agent
03/19/2009WO2009033721A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
03/19/2009WO2009033720A1 Mastoparan for the treatment of diseases
03/19/2009WO2009033719A2 Use of a deslorelin and mastoparan as a therapeutic agent
03/19/2009WO2009033718A2 Use of anti -inflammatory peptide 1 as a therapeutic agent
03/19/2009WO2009033717A2 Use of gonadorelin as a therapeutic agent
03/19/2009WO2009033714A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033712A2 Use of melanotan ii as a therapeutic agent
03/19/2009WO2009033711A2 Use of glp-1 as a therapeutic agent
03/19/2009WO2009033710A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009WO2009033707A2 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
03/19/2009WO2009033701A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033700A1 Use of secretin and optionally urodilatin as therapeutic agents
03/19/2009WO2009033696A1 Use of a peptide pyx-1 as a therapeutic agent
03/19/2009WO2009033692A2 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
03/19/2009WO2009033690A1 Bfgf (119-126) for therapeutic applications
03/19/2009WO2009033689A1 Piperidone derivatives and medical uses thereof
03/19/2009WO2009033687A1 Spantide ii and bfgf (119-126) for therapeutic applications
03/19/2009WO2009033684A1 Minigastrin as a therapeutic agent
03/19/2009WO2009033681A2 Cyclo-argd as a therapeutic agent
03/19/2009WO2009033680A2 Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
03/19/2009WO2009033669A2 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
03/19/2009WO2009033666A2 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
03/19/2009WO2009033665A2 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
03/19/2009WO2009033664A1 Use of delta-endorphin as a therapeutic agent
03/19/2009WO2009033663A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009WO2009033661A2 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
03/19/2009WO2009033660A2 Use of octreotide as a therapeutic agent
03/19/2009WO2009033659A1 Hcv protease inhibitor and octreotide as therapeutic agents
03/19/2009WO2009033658A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009WO2009033657A2 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
03/19/2009WO2009033656A2 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
03/19/2009WO2009033581A1 Substituted tricyclic compounds and methods of use thereof
03/19/2009WO2009033505A1 Hellebrin derivatives
03/19/2009WO2009033411A1 Method and composition for cancer diagnosis and treatment
03/19/2009WO2009033406A1 Modified recombinant human endostatin and its application
03/19/2009WO2009033293A1 Protein tyrosine phosphatase 1b and cancer
03/19/2009WO2009033284A1 Inhibitors of collagen biosynthesis as anti-tumor agents
03/19/2009WO2009033281A1 Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
03/19/2009WO2009033278A1 Bovine herpesvirus type 1 for cancer therapy
03/19/2009WO2009033259A1 An anti-cancer cytotoxic monoclonal antibody
03/19/2009WO2009033233A1 Novel p2x7 epitopes
03/19/2009WO2009033212A1 The use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
03/19/2009WO2009033204A1 Multi-component compositions and methods for delivery of anti-cancer agents
03/19/2009WO2009018551A3 Therapeutic compounds
03/19/2009WO2009017823A3 A fold-back diabody diphtheria toxin immunotoxin and methods of use
03/19/2009WO2009007536A3 Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
03/19/2009WO2009007390A3 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
03/19/2009WO2009007348A3 Use of antagonists of g protein coupled receptors (gpcrs) for treating diseases caused by agonistic autoantibodies activated gpcrs
03/19/2009WO2009006567A3 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
03/19/2009WO2009003669A3 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
03/19/2009WO2008155141A3 Novel facultative catonic sterols
03/19/2009WO2008143954A3 Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
03/19/2009WO2008138878A3 Novel pyridopyrazine derivatives, process of manufacturing and uses thereof
03/19/2009WO2008135886A3 Quinoline derivatives for use in the inhibition of the growth of tumour cells
03/19/2009WO2008116157A3 Mesenchymal stem cells and uses therefor
03/19/2009WO2008108808A3 Complexes derived from heterohybrid cells and uses thereof
03/19/2009US20090076267 Transition metal phosphine complex, method for producing same, and anticancer agent containing transition metal phospine complex
03/19/2009US20090076250 recognize selectively both Programmed Death 1 (PD-1) protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1; for medical treatment and/or prevention of diseases caused by immune abnormality
03/19/2009US20090076176 Prodrugs activated by plasmin and their use in cancer chemotherapy
03/19/2009US20090076154 Deuterium-enriched vorinostat
03/19/2009US20090076139 Deuterium-enriched oxalplatin
03/19/2009US20090076131 Anti-Cancer and Anti-Inflammatory Effects of Annurca Apple Extracts and Compositions Purified Therefrom
03/19/2009US20090076130 Compounds for the inhibition of histone deacetylase
03/19/2009US20090076127 Deuterium-enriched larotaxel
03/19/2009US20090076123 Medical Compositions for Intravesical Treatment of Bladder Cancer
03/19/2009US20090076122 PARP Modulators and Treatment of Cancer
03/19/2009US20090076103 Stem cell differentiating agents and uses therefor
03/19/2009US20090076099 Deuterium-enriched ixabepilone
03/19/2009US20090076098 Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
03/19/2009US20090076073 Therapeutic amides
03/19/2009US20090076070 Hetero compound
03/19/2009US20090076060 Deuterium-enriched temsirolimus
03/19/2009US20090076058 Deuterium-enriched finasteride
03/19/2009US20090076057 Deuterium-enriched dutasteride
03/19/2009US20090076055 Deuterium-enriched vinflunine
03/19/2009US20090076050 Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer
03/19/2009US20090076046 Compounds modulating c-fms and/or c-kit activity and uses therefor
03/19/2009US20090076044 Vegfr inhibitors containing a zinc binding moiety
03/19/2009US20090076042 Deuterium-enriched erlotinib
03/19/2009US20090076037 Bicyclic pyrimidine kinase inhibitors
03/19/2009US20090076034 Deuterium-enriched bms-690514
03/19/2009US20090076031 Deuterium-enriched bortezomib
03/19/2009US20090076025 Deuterium-enriched dasatinib
03/19/2009US20090076017 Deuterium-enriched trabectedin
03/19/2009US20090076016 Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases
03/19/2009US20090076011 Deuterium-enriched tirapazamine
03/19/2009US20090076009 Thiazole derivatives and their use as anti-tumour agents
03/19/2009US20090076006 Hsp90 inhibitors containing a zinc binding moiety
03/19/2009US20090076005 Kinase inhibitor compounds
03/19/2009US20090076003 Phthalazine Derivatives with Angiogenesis Inhibiting Activity
03/19/2009US20090075989 Non-steroidal progesterone receptor modulators
03/19/2009US20090075981 INHIBITORS OF p38
03/19/2009US20090075980 Pyrazolopyridines and Analogs Thereof
03/19/2009US20090075972 Use of Midostaurin for Treating Gastrointestinal Stromal Tumors
03/19/2009US20090075952 Nitroderviatives as drugs for diseases having an inflammatory basis
03/19/2009US20090075945 Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents
03/19/2009US20090075941 Treating neoplasms
03/19/2009US20090075936 Proteasome inhibitors and methods of using the same
03/19/2009US20090075932 METHOD OF SELECTIVELY INHIBITING PKCiota
1 ... 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 ... 2211